People with type 2 diabetes who are unable to adequately manage their blood glucose levels with insulin alone exhibited improved results when Actos® (pioglitazone HCl) was added to their treatment regimen, according to a study published in the May issue of the International Journal of Clinical Practice.
Results from the clinical study show that Actos, used in combination with a stable insulin regimen, decreases fasting plasma glucose levels and improves blood glucose control as measured by glycosylated hemoglobin A1C (HbA1c), an estimate of blood glucose levels for a patient during the preceding 90 – 120 days. Actos is an insulin resistance reducer, and the only thiazolidinedione (TZD) approved for use in combination with insulin.
People with insulin resistance are unable to effectively use the insulin their bodies produce, which is a core metabolic defect of type 2 diabetes. “The main goal in managing diabetes is maintaining appropriate blood glucose levels, and for some patients with type 2 diabetes, conventional insulin alone may not be sufficient,” said Julio Rosenstock, M.D., at the Dallas Diabetes and Endocrine Center in Texas, and the study’s lead investigator.
“We’re very encouraged by these study results because they present a viable option for patients who have hit a roadblock with their current conventional insulin treatment. The study required the insulin doses to remain unchanged to allow proper analysis of the specific effects of Actos. Further improvements in glycemic control could potentially be achieved if more dynamic and physiologic insulin regimens are used in clinical practice.”
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!